Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy^*

References

• Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol. 2007;138:430–445.
   PubMed Web of Science ®Google Scholar
• Mitchell L, Hoogendoorn H, Giles AR, et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. Blood. 1994;83:386–391.
   PubMed Web of Science ®Google Scholar
• Mitchell LG, Halton JM, Vegh PA, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol. 1994;16:120–126.
   PubMedGoogle Scholar
• Elliott MA, Wolf RC, Hook CC, et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma. 2004;45:1545–1549.
   PubMed Web of Science ®Google Scholar
• Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152:452–459.
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Mazzucconi MG, Leone G, et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol. 1992;49:63–66.
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93:1488–1494.
   PubMed Web of Science ®Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52:2237–2253.
   PubMed Web of Science ®Google Scholar
• Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003;90:235–244.
   PubMed Web of Science ®Google Scholar
• Farrell K, Fyfe A, Allan J, et al. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events. Leuk Lymphoma 2016;57:2568–2574.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network, Acute Lymphoblastic Leukemia. (Version 2.2016); [cited 2016 Sep]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf.
   Google Scholar
• Thrombate III®. Antithrombin III hpiRTP, NC. Grifols Therapeutics Inc.; 2013.
   Google Scholar
• Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer. 2003;97:508–516.
   PubMed Web of Science ®Google Scholar
• Gugliotta L, D'Angelo A, Mattioli Belmonte M, et al. Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo. Br J Haematol. 1990;74:465–470.
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Gugliotta L, Leone G, et al. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study. Blood Coagul Fibrinolysis. 1994;5:23–28.
   PubMed Web of Science ®Google Scholar
• Mattioli Belmonte M, Gugliotta L, Delvos U, et al. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase. Haematologica. 1991;76:209–214.
   PubMed Web of Science ®Google Scholar
• Kimura S, Oshima K, Sato K, et al. Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010;16:1355–1361.
   PubMed Web of Science ®Google Scholar
• Kimura S, Wada H, Ishihara Y, et al. D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine. Hematology. 2014;19:107–112.
   PubMed Web of Science ®Google Scholar
• Kimura SI, Wada H, Sakamoto K, et al. L-index as a novel index to evaluate both the intensity and duration of lymphopenia after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2012;14:364–373.
   PubMed Web of Science ®Google Scholar
• Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. JCO. 2009;27:3849–3854.
   PubMed Web of Science ®Google Scholar
• Lauw MN, Van der Holt B, Middeldorp S, et al. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: effect of fresh frozen plasma supplementation. Thromb Haemost. 2013;109:633–642.
   PubMed Web of Science ®Google Scholar
• Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. JCO. 2005;23:4063–4069.
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. JCO. 2005;23:4057–4062.
   PubMed Web of Science ®Google Scholar
• Abbott LS, Deevska M, Fernandez CV, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood. 2009;114:5146–5151.
   PubMed Web of Science ®Google Scholar
• Kurre HA, Ettinger AG, Veenstra DL, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children’s Cancer Group study (CCG-1962). J Pediatr Hematol Oncol. 2002;24:175–181.
   PubMed Web of Science ®Google Scholar